Amyotrophic lateral sclerosis (ALS) is a rare, progressing disease in which motor neurons degenerate or die diminishing the signals that control muscle function.
Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints.
A Review article summarizing the Potential of Levosimendan in the Management of ALS: Overview of a Working Hypothesis
The beginning and progression of ALS symptoms vary between people. The treatment is planned by a multi-professional team in cooperation with the patient. The patients’ families need support as well.
